| ZHANG Li,YANG Mei.Curative effects, prognostic factors, and adverse reactions of different treatment modalities of chemotherapy in patients with non-small cell lung cancer[J].Chinese Journal of Radiological Medicine and Protection,2011,31(1):50-54 |
| Curative effects, prognostic factors, and adverse reactions of different treatment modalities of chemotherapy in patients with non-small cell lung cancer |
| Received:May 18, 2010 |
| DOI：10.3760/cma.j.issn.0254-5098.2011.01.013 |
| KeyWords:Non-small cell lung cancer Radiotherapy Chemotherapy Treatment efficacy Toxicity |
| FundProject: |
|
| Hits: 3695 |
| Download times: 2663 |
| Abstract:: |
| Objective To explore the curative effects, prognostic factors, and adverse reactions of different treatment modalities of chemotherapy in patients with non-small cell lung cancer (NSCLC). Methods 151 NSCLC patients were randomly assigned into 3 groups to undergo concurrent chemo-radiotherapy (n=43), sequential chemo-radiotherapy (n=49), or pure chemotherapy (n=59). The clinical data were analyzed. Results The short-term effective rates of the concurrent and sequential chemo-radiotherapy groups were 81.4% and 73.5% respectively with no significantly difference between them, but both significantly higher than that of the pure chemotherapy group (39.0%, both P<0.05). The mortality of the concurrent chemo-radiation group was 53.5%, significantly lower than those of the sequential chemo-radiotherapy and pure chemotherapy groups (67.3% and 67.8% respectively, both P＜0.05). The median survival time of the concurrent chemo-radiotherapy group was 26 months, significantly longer than those of the sequential chemo-radiotherapy and pure chemotherapy groups (12 and 11 months respectively, both P＜0.05). The 1-year survival rates of the 3 groups were 80.2%, 47.1%, and 45.6%. The 2-year survival rates were 58.2%, 38.5%, and 24.4%, and the 3-year survival rates were 32.7%, 27.5%, and 0, respectively. The white blood cell decrease rates of the grades Ⅲ~Ⅳ of the concurrent chemo-radiotherapy group were significantly higher than those of the other 2 groups (both P<0.05). There were no significant differences in the rates of radiation esophagitis and radiation pneumonitis between the concurrent and sequential chemo-radiotherapy groups. Age, performance status score, clinical staging, and treatment modality were the 4 influencing factors in the prognosis of NSCLC (all P＜0.05). Conclusion Relatively safe with tolerable adverse reactions, concurrent chemo-radiotherapy is superior to sequential chemo-radiotherapy, particularly to pure chemotherapy, in increase of median survival time and survival rate in treatment of NSCLC. Age, PS, clinical staging and therapy method are independent indicators influencing the prognosis. |
| HTML View Full Text View/Add Comment Download reader |
| Close |
|
|
|
